About Us

Our Mission Statement

Ornovi is an early stage biotechnology company focused on changing the treatment paradigm for patients suffering from inflammatory/immunology disorders. Our initial focus is in the inflammatory skin conditions, starting with Alopecia Areata and Vitiligo, where there is a tremendous opportunity to provide patients with better and safer treatments. Our lead program, OR-101 is a next generation highly selective JAK3, with a dual inhibition with ITK, with potential to open up new treatment options for patients who cannot benefit from the marketed products.

Leadership

Biopharmaceutical industry veterans with experience working for both big pharma (Allergan, Regeneron, AstraZeneca, Incyte) and small startups (Bonti, Kythera) in various leadership roles. Experienced drug developers with several patents and research publications, along with contribution to the development and approval of several drugs. Exemplary track records in launching biotech startups (Bonti) leading to successful exits (Bonti – ~$0.2B + milestones, Kythera – $2.1B). Additional team members/advisors include accomplished individuals in the field of Immunology/Inflammatory (I&I)

Fauad Hasan
// Chief Executive Officer

Patricia Walker, M.D. Ph.D.
// Head of Clinical Development

Wajdie Ahmad
// Chief Operating Officer